Market news
In the closing of the recent trading day, Novavax (NVAX) stood at $10.79, denoting a +1.53% move from the preceding trading day.
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
In the most recent trading session, Novavax (NVAX) closed at $10.11, indicating a +1.1% shift from the previous trading day.
Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Legislative headlines, not company announcements, have been steering attention toward Novavax (NVAX). Bipartisan lawmakers recently introduced the Protecting Approved Care Act, and the proposal has weighed on several healthcare stocks, including this vaccine developer. Recent trading reflects that pressure. Novavax’s share price is down 3.75% over the last day and 9.42% over the past week. The 30-day share price return of 14.66% feeds into a stronger year-to-date gain of 29.45% and a more...
Earlier this month, Novavax participated in investor-focused healthcare conferences hosted by Citigroup and Cantor Fitzgerald in New York, outlining its vaccine and partnership positioning to a broad institutional audience. Around the same time, bipartisan lawmakers introduced the Protecting Approved Care Act, stirring concern across healthcare names like Novavax about potential changes to Medicare Advantage reimbursement practices and administrative requirements. We’ll now examine how...
A number of stocks fell in the morning session after bipartisan lawmakers introduced the Protecting Approved Care Act, legislation aimed at reforming prior authorization and payment rules in Medicare Advantage plans.
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
A number of stocks jumped in the morning session after Morningstar reported that challenging macroeconomic conditions across broader equity markets drove a rotation into healthcare, lifting the sector index by approximately 7% quarter-to-date to reach a 5% valuation premium.
In the most recent trading session, Novavax (NVAX) closed at $9.42, indicating a +1.29% shift from the previous trading day.
Novavax, Inc. (Nasdaq: NVAX) today announced that company management will participate in the following upcoming investor conferences:
Retail traders are piling into Novavax on cancer-vaccine speculation, but the move that actually changed the company's business model happened quietly last week and has nothing to do with oncology.
Novavax reported that partners Sanofi and Takeda have secured approvals for an updated Nuvaxovid formulation targeting the SARS-CoV-2 XFG variant for the 2026–2027 vaccination season across the U.S., European Union, Japan, and other major markets. These approvals allow Novavax to participate in the upcoming COVID-19 vaccination season primarily through royalties and milestones, while its partners shoulder the commercial execution and infrastructure burden. We'll now examine how Novavax’s...
Novavax (NVAX) drew fresh attention after announcing that partners secured approvals for an updated Nuvaxovid formulation targeting the SARS CoV 2 XFG variant for the 2026 to 2027 vaccination season. The news has arrived after a mixed period for Novavax’s stock. The share price is up 26.16% over the past 30 days and 29.87% year to date, yet down 15.59% over 90 days. The 1 year total shareholder return sits at 23.96%, while the 5 year total shareholder return reflects a steep 96.32% decline,...
Novavax stock has delivered a sharp 5 year decline alongside a recent rebound, and the broader valuation checks now point to a mixed picture rather than a clear bargain or clear overvaluation at the current price. The share price return over 5 years is down 96.3%, which signals that long term holders have absorbed very heavy losses despite the recent bounce. Future demand for Novavax products and the company’s ability to convert that demand into steady cash flow can support the equity story,...
The FDA approved Moderna, Novavax-Sanofi and Pfizer-BioNTech's updated COVID vaccines, the companies said on Aug. 27.
Novavax stock is garnering attention from options traders
This is the newest page. Registered accounts read further back.